Core Insights - Aclarion, Inc. has completed the first Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway, which compares lumbar interbody fusion surgery with multidisciplinary rehabilitation for chronic low back pain [1][2] - The LIFEHAB Trial involves 202 patients with low back pain lasting over one year and aims to evaluate the effectiveness of Nociscan technology in identifying treatment responses through magnetic resonance spectroscopy (MRS) biomarkers [1][2] - Aclarion anticipates that the results from the LIFEHAB trial will contribute to achieving successful reimbursement in national health insurance systems, such as Norway's [3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to help physicians identify painful discs in the lumbar spine [4] - Nociscan is described as the first evidence-supported SaaS platform that noninvasively distinguishes between painful and nonpainful discs, providing critical insights for optimizing treatment strategies [4] Market Position and Future Outlook - The company is experiencing accelerated adoption of Nociscan in the research market and is looking to establish more partnerships to enhance its presence [3] - Aclarion is awaiting results from a completed trial in Rome and two NIH studies that also evaluate the role of Nociscan in treating chronic low back pain [2][3]
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial